As of Nov 30
| 0.00 / 0.00%|
The 7 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 42.00, with a high estimate of 65.00 and a low estimate of 35.00. The median estimate represents a +9.98% increase from the last price of 38.19.
The current consensus among 9 polled investment analysts is to Hold stock in Acorda Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.